Back to Results

Screening for AL Amyloidosis in SMM

Title Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Therapeutic Area Multiple Myeloma
Principal Investigator Raymond Comenzo, MD
Min Age 40 Years
Gender Any
Contact Latoya Lashley


In response to the significant need to intensify efforts at early diagnosis, this trial proposes further building on knowledge of the genetic basis of AL in clonal plasma cells. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease. 

Study Details

Inclusion Criteria

Patients 40 years of age and older diagnosed with )SMM with dFLC greater than 23 mg/L and abnormal κ::λ FLC ratio

Exclusion Criteria

Patients with MGUS or with a previous finding of amyloid in other biopsies will not be included. Patients younger than 40 years of age are not eligible.

Study Requirements

One-time donation of bone marrow and peripheral blood samples.